PubMed Health⌕ Search

Biomedical subjects

S Bravi

Publications and source records attributed to S Bravi.

6 recordsLinked to original sources
PubMed1998

Amyloid tumours in the soft tissues of the legs. Case report and review of the literature.

We present a case of multiple amyloidomas occurring in the calves of a 61-year-old woman, without systemic amyloidosis or plasma cell dyscrasia. The disappearance of Congo red positivity after potassium permanganate treatment and immunohistochemical results showed that this was a case of reactive AA amyloidosis. True soft tissue amyloidomas are extremely rare, and this is the first case of AA amyloidoma in the soft tissues of the legs.

Amyloid↗
PubMed1996

Emotional information processing and visual evoked brain potentials.

Visual evoked potentials to emotional slides presented for 2 sec. were investigated in 13 subjects. 73 emotional slides (pleasant, unpleasant, and neutral) were selected from a standardized set of photographic slides, the 1988 International Affective Picture System of Lang, Ohman, and Vaitl Visual evoked potentials were recorded from three head locations, frontal, central and parietal (Fz, Cz, and Pz). Analyses were performed in the two latency ranges: 300-400 msec. and 400-500 msec. Analyses showed an arousal effect, as indicated by a quadratic trend, indicating that emotional slides (both pleasant and unpleasant) gave higher cortical positivity than neutral ones, for all components. In addition, in the two latency epochs, larger positivities were found at Pz, compared to Fz and Cz, whereas Fz and Cz did not differ from each other.

Adult↗
PubMed1980

[Erythrocyte membrane in Duchenne muscular dystrophy. I. Sensitivity to lysolecithin in dystrophic patients and their families].

The percentage of echinocytes in the blood from patients affected by Duchenne muscular Distrophy was studied after red cells treatment with L-alpha-lysophosphatidylcholine. The echinocyte content was significantly higher in Duchenne patients and in the components of their families, as previously demonstrated is lower in Stainert patients. The sensitivity to lysophosphatidylcholine in Duchenne muscular Distrophy is a diagnostic test for carrier condition

Erythrocyte Membrane↗
PubMedDate not supplied

CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer.

The diagnosis of pancreatic cancer is usually made in the advanced stages of the disease when the prognosis is poor. We compared the behavior of CA19.9, CEA and the newly proposed mucin CA242 in a consecutive series of 42 pancreatic carcinomas. A control group was recruited of 21 patients with benign pancreatic diseases. With the recommended cutoffs (37 U/ml for CA19.9, 20 U/ml for CA242 and 8 ng/ml for CEA) we obtained a specificity of 90% for CA19.9 and of 85% for CA242 and CEA. The sensitivity was 85.7% for CA19.9, 73.8% for CA242 and 26.2% for CEA. CA19.9 and CA242 showed identical behavior in various TNM stages of cancer and in stages III and IV of the Hermreck classification. Moreover, CA19.9 and CA242 showed identical behavior in 10 patients monitored during the survival period who developed recurrence of disease. ROC curve evaluation demonstrated that CA242 and CA19.9 were very similar. The results of CA242 were better than those of CA19.9 in the false positive range under 10%, whereas CA19.9 had a better performance in the true positive range over 70%. CA242 could be used instead of CA19.9 for diagnosing pancreatic carcinoma.

Antigens, Tumor-Associated, Carbohydrate↗
PubMedDate not supplied

Are diabetic metabolic compensation and CA19.9 really correlated?

Diabetes has been claimed to be a risk factor for pancreatic carcinoma, but it is probably a consequence of gland invasion from the neoplastic tissue. A link between diabetes and pancreatic carcinoma was suggested by means of biochemical markers of the diseases, namely glycated hemoglobin and CA19.9. Moreover, CA19.9 was proposed as a sensitive and useful marker of the severity of exocrine damage in diabetes, since the mucin decreased when metabolic compensation improved. We examined 64 diabetic patients (36 insulin dependent, 16 non insulin dependent, 12 treated with diet) by measuring CA19.9 using two different immunometric methods and glycemia and glycated hemoglobin. We observed that a correlation between CA19.9 and biochemical markers of metabolic compensation of diabetes was inexistent and no differences between insulin dependent and non insulin dependent patients were found. A high concentration of CA19.9 in a diabetic patient should be interpreted and evaluated in the same manner as for a non diabetic patient.

Adult↗